Journal article
Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma
Gynecologic oncology, Vol.124(1), pp.36-41
01/2012
DOI: 10.1016/j.ygyno.2011.09.022
PMID: 22015042
Abstract
To determine the outcomes associated with primary radiation therapy for medically inoperable, clinical stage I and II, endometrial adenocarcinoma (EAC).
A multi-institution, retrospective chart review from January 1997 to January 2009 was performed. Overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS) and time to progression (TTP) were assessed using the Kaplan–Meier method. Disease-specific survival was analyzed using a competing risks approach.
Seventy-four patients were evaluable. The median age and BMI were 65years (range 36–92years) and 46kg/m2 (range 23–111kg/m2), respectively. 85.1% had severe systemic disease, most frequently cardiopulmonary risk and morbid obesity. With a mean follow-up of 31months, 13 patients (17.6%) experienced a recurrence. The median PFS and OS were 43.5months and 47.2months, respectively. Overall, 35 women died, including 4 women who died of unknown cause. Of the remaining 31 women, 7 patients (9.5%) died of disease, while 24 died of other causes (32.4%). The hazard ratio comparing the risk of death due to other causes to the risk of death due to disease was 3.4 (95% CI 1.4–9.4, p=0.003). Among patients who are alive three years after diagnosis, 14% recurred and the conditional recurrence estimate did not exceed 16%.
Primary radiation therapy for clinical stage I and II EAC is a feasible option for medically inoperable patients and provides disease control, with fewer than 16% of surviving patients experiencing recurrence.
► Primary radiation therapy for stage I and II endometrial cancer is a feasible option. ► The probability of cancer recurrence in patients receiving such treatment is 15%. ► These patients are 3.4 times likely to die from causes other than endometrial cancer.
Details
- Title: Subtitle
- Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma
- Creators
- Iwona Podzielinski - Division of Gynecologic Oncology, University of Kentucky, Lexington, KY, USAMarcus E Randall - Division of Radiation Oncology, University of Kentucky, Lexington, KY, USAPatrick J Breheny - Department of Biostatistics, University of Kentucky, Lexington, KY, USAPedro F Escobar - Division of Gynecologic Oncology, Cleveland Clinic, Cleveland, OH, USADavid E Cohn - Division of Gynecologic Oncology, The Ohio State University, Columbus, OH, USAAllison M Quick - Division of Radiation Oncology, The Ohio State University, Columbus, OH, USAJunzo P Chino - Division of Radiation Oncology, Duke University Medical Center, Durham, NC, USAMicael Lopez-Acevedo - Division of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USAJana L Seitz - Division of Gynecologic Oncology, Indiana University, Indianapolis, IN, USAJennifer E Zook - Division of Radiation Oncology, Indiana University, Indianapolis, IN, USALeigh G Seamon - Division of Gynecologic Oncology, University of Kentucky, Lexington, KY, USA
- Resource Type
- Journal article
- Publication Details
- Gynecologic oncology, Vol.124(1), pp.36-41
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.ygyno.2011.09.022
- PMID
- 22015042
- ISSN
- 0090-8258
- eISSN
- 1095-6859
- Language
- English
- Date published
- 01/2012
- Academic Unit
- Biostatistics
- Record Identifier
- 9983997338302771
Metrics
21 Record Views